Metsera, Inc.’s Quiet Period Set To End on March 12th (NASDAQ:MTSR)

Metsera’s (NASDAQ:MTSR) quiet period will end on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on MTSR shares. Guggenheim started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating for the company. Evercore ISI assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an “outperform” rating on the stock. Finally, Bank of America assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective on the stock.

Metsera Price Performance

Shares of Metsera stock opened at $25.47 on Friday. Metsera has a 52-week low of $24.19 and a 52-week high of $32.81.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.